U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults MerckFDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections CNBCMerck’s vaccine approval poses threat to one of Pfizer’s top-selling products MarketWatchNew Merck pneumococcal vaccine wins FDA approval STATMerck Wins US Approval for Pneumonia Vaccine to Rival Pfizer’s Bloomberg